-
2008
27 November 2008: Announcement no. 3, 2008: Zealand Pharma and Helsinn Healthcare S...
-
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 1 compound in phase II, 2 c...
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 1 compound in phase II, 2 compounds in phase I, and 3 compounds in pre-clinical development.
The development of Rotigaptide (ZP123, GAP-486) for arrhythmia (licensed to Wyeth) and of ZP120 for acute heart failure has been terminated after Phase II clinical trials.
The following table summarizes the status of Zealand Pharma's current product pipeline.
|
Product Candidate |
Indication |
Commercial Partner |
Status |
|
Phase III - initialized 2008. |
|||
|
Post-surgical Organ Failure |
Action Pharma |
Phase II – Initiated in 2008 |
|
|
Phase I – single dose, safety and tolerability trial. Finalized 2008 |
|||
|
Phase I – single dose, safety and tolerability trial started October 2007. |
|||
|
|
Preclinical |
||
| ZP2307 | Osteoporosis | Preclinical | |
|
|
Preclinical |
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.